NCT07351266Not yet recruiting
Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors
Source: ClinicalTrials.gov · Last updated 20 Jan 2026
Brief summary (registry, in English)
This is a research study aiming to better understand a type of kidney cancer called Renal Cell Carcinoma (RCC). Doctors have observed that inside some larger RCC tumors, there are multiple smaller nodules. This study wants to find out if these nodules are different from each other and how they might be related. To do this, researchers will study tumor tissue samples from 10 patients with RCC who are having surgery. From each tumor, several nodules will be analyzed using advanced laboratory techniques. These techniques will create very detailed maps of the genes and cells within each nodule. At the same time, tiny 3D tumor models (called microtumors) will be grown from these samples in the lab to test how they respond to different cancer drugs. The main goal is to combine these two types of information to see how the differences in genes and cells between nodules might explain why some tumors stop responding to treatment (become resistant). We hope this study will lead to a deeper understanding of how RCC grows and spreads, and help find new ways to diagnose and treat it in the future.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 10 (estimated)
- First submitted
- 12 Jan 2026
- Start date
- 25 Jan 2026
- Primary completion date
- 25 Jan 2028
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Diseases
- Kidney cancer
- NCT number
- NCT07351266
What you commit to
- Study type: Observational
- Planned participants: 10
- From 25 Jan 2026 to the primary completion date, 25 Jan 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior receipt of any targeted therapy or immunotherapy for renal cell carcinoma before surgery.
Other illness
- History of other active malignancies besides RCC (except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix).
- Any psychiatric, neurological, or legal condition that may compromise the ability to understand the informed consent or to comply with study procedures.
Other
- Presence of distant metastasis (M1 stage).
Who the study is looking for
- Histologically confirmed renal cell carcinoma with regional lymph node metastasis.
- Primary tumor with a maximum diameter ≥ 7 cm.
- Tumor exhibits a multinodular distribution pattern on cross-section (assessed via intraoperative or postoperative gross specimen).
- Age \> 18 years.
- Ability to understand the study and voluntarily provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.